Explore

Rapid Read Rapid Read
U.S. Faces Challenges in Maintaining Lead in Rare Disease Drug Development

U.S. Faces Challenges in Maintaining Lead in Rare Disease Drug Development

A report by the National Security Commission on Emerging Biotechnology warns that the U.S. is losing its lead in rare disease drug development, posing a national security risk. The report highlights China's rapid progress in biotech innovation, driven by accelerated clinical trial pathways and active participant recruitment. The U.S. government's current policies focus more on curbing Chinese influence rather than bolstering domestic drug development. However, initiatives like the FDA's pilot program to improve clinical trial protocols aim to expedite drug development. The report calls for supportive policies to maintain U.S. competitiveness in this critical sector.
Trendline Trendline
Arrowhead Pharmaceuticals Reports Positive Phase 3 Data for Triglyceride-Lowering Drug

Arrowhead Pharmaceuticals Reports Positive Phase 3 Data for Triglyceride-Lowering Drug

Arrowhead Pharmaceuticals Reports Positive Phase 3 Data for Triglyceride-Lowering Drug
Rapid Read Rapid Read
FDA Panel Considers Easing Restrictions on Peptide Therapies Amid Safety Concerns

FDA Panel Considers Easing Restrictions on Peptide Therapies Amid Safety Concerns

An FDA advisory panel is reviewing the potential easing of restrictions on several peptide therapies, including TB-500, BPC-157, and MOTs-C. These peptides are promoted for benefits such as injury recovery and muscle growth but lack large-scale clinical trials to confirm their safety and efficacy. The panel's review comes amid a growing gray market for these substances, driven by current restrictions. The FDA scientists have recommended against allowing compounding pharmacies to produce these peptides due to limited human data. The panel will vote on recommendations, but the final decision rests with FDA leadership.
Rapid Read Rapid Read
Science Corporation's Vision-Restoring Chip Gains EU Approval

Science Corporation's Vision-Restoring Chip Gains EU Approval

Science Corporation has received approval from Europe's medical device regulator to market its PRIMA device, a vision-restoring chip for patients with age-related macular degeneration. The device involves an outpatient procedure to implant a chip in the eye, which works with camera-equipped glasses to restore functional vision. The company is also pursuing expedited regulatory review from the U.S. FDA for treating rare blindness conditions. Science Corp. plans to offer the device in Germany, with the first procedures expected in September. The company aims to develop a sustainable business model to support further innovations in brain-computer interfaces.
Rapid Read Rapid Read
Rapid Medical Gains FDA Clearance for DRIVEWIRE 35, Enhancing Stroke Treatment

Rapid Medical Gains FDA Clearance for DRIVEWIRE 35, Enhancing Stroke Treatment

Rapid Medical has received FDA clearance for its DRIVEWIRE 35, a steerable guidewire designed to improve access during stroke and other intravascular procedures. This device allows physicians to navigate complex vascular anatomy more efficiently, potentially reducing the need for additional devices and saving critical time during procedures. The clearance was announced at the Society of NeuroInterventional Surgery's annual meeting, marking a significant advancement in stroke treatment technology.
Rapid Read Rapid Read
New Center for Therapeutic Genetics Launched to Tackle Rare Diseases

New Center for Therapeutic Genetics Launched to Tackle Rare Diseases

The Broad Institute, Boston Children's Hospital, and The Jackson Laboratory have launched the Center for Therapeutic Genetics (CTG) to develop genetic medicines for rare and ultra-rare diseases. The collaboration aims to create precision medicines using advanced genetic editing techniques like base and prime editing. The center will focus on making these treatments scalable and accessible, sharing methods and data to facilitate broader application.
Trendline Trendline
Ashlins Pharmaceuticals Secures Exclusive License with Lee's Pharm for Interferon Alpha-2b Development

Ashlins Pharmaceuticals Secures Exclusive License with Lee's Pharm for Interferon Alpha-2b Development

Ashlins Pharmaceuticals Secures Exclusive License with Lee's Pharm for Interferon Alpha-2b Development
Trendline Trendline
Agios Pharmaceuticals Discontinues Sickle Cell Drug Candidate After Failing to Outperform Competitors

Agios Pharmaceuticals Discontinues Sickle Cell Drug Candidate After Failing to Outperform Competitors

Agios Pharmaceuticals Discontinues Sickle Cell Drug Candidate After Failing to Outperform Competitors
Trendline Trendline
Scholar Rock Updates on Apitegromab MAA Review Amid FDA Inspection Uncertainty

Scholar Rock Updates on Apitegromab MAA Review Amid FDA Inspection Uncertainty

Scholar Rock Updates on Apitegromab MAA Review Amid FDA Inspection Uncertainty
Trendline Trendline
Summit and Akeso Present Promising Western Data for Ivonescimab in Lung Cancer Treatment

Summit and Akeso Present Promising Western Data for Ivonescimab in Lung Cancer Treatment

Summit and Akeso Present Promising Western Data for Ivonescimab in Lung Cancer Treatment
Trendline Trendline
FDA to Review Safety and Efficacy of Synthetic Peptides Amid Growing Hype

FDA to Review Safety and Efficacy of Synthetic Peptides Amid Growing Hype

FDA to Review Safety and Efficacy of Synthetic Peptides Amid Growing Hype
Trendline Trendline
Arcturus Therapeutics to Showcase Innovations at Growth Conference

Arcturus Therapeutics to Showcase Innovations at Growth Conference

Arcturus Therapeutics to Showcase Innovations at Growth Conference